METHOD FOR PREVENTING HIV-1 INFECTION OF CD4<+> CELLS

Abstract: This invention provides methods for inhibiting fusion of HIV-1 to CD4<+> cells which comprise contacting CD4<+> cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4<+> cells is inhibited. This invention also provides methods for inhibiting HIV-1 infection of CD4<+> cells which comprise contacting CD4<+> cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4<+> cells is inhibited, thereby inhibiting the HIV-1 infection. This invention provides non-chemokine agents capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4<+> cells. This invention also provides pharmaceutical compositions comprising an amount of the non-chemokine agent capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4<+> cells effective to prevent fusion of HIV-1 to CD4<+> cells and a pharmaceutically acceptable carrier.

Description: METHOD FOR PREVENTING HIV-1 INFECTION OF CD4 + CELLS This application is a continuation-in-part of U.S. Serial No. 08/673,682, filed June 25, 1996, which is a continuation-in- part of U.S. Serial No. 08/663,616, filed June 14, 1996, which is a continuation-in-part of U.S. Serial No. 08/627,684, filed April 2, 1996, the content of which are incorporated by reference into this application. Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic citation for these references may be found at the end of each series of experiments. Background of the Invention Chemokines are a family of related soluble proteins of molecular weight between 8 and lOKDa, secreted by lymphocytes and other cells, which bind receptors on target cell surfaces resulting in the activation and mobilization of leukocytes, for example in the inflammatory process. Recently, Cocchi et al. demonstrated that the chemokines RANTES, MlP-lα and MlP-lβ are factors produced by CD8 4 T lymphocytes which inhibit infection by acrophage-tropic primary isolates of HIV-1, but not infection by laboratory-adapted strains of the virus (1) . These chemokines are members of the C-C group of chemokines, so named because they have adjacent cysteine residues, unlike the C-X-C group which has a single amino acid separating these residues (2) . While Cocchi et al. found that expression of HIV-1 RNA was suppressed by treatment with the chemokines, they did not identify the site of action of these molecules. A resonance energy transfer (RET) assay of HIV-1 envelope glycoprotein-mediated membrane fusion was used to determine whether fusion mediated by the envelope glycoprotein from the primary acrophage- ropic isolate of HIV-1 JR . FI would be specifically inhibited by chemokines, when compared with fusion mediated by the envelope glycoprotein from the laboratory-adapted T lymphotropic strain HIV-l^. As described below, it was demonstrated that this is indeed the case. This demonstrates that some chemokine receptors are fusion accessory molecules required for HIV-1 infection. Previous studies have indicated that unidentified cell surface molecules are required for virus entry in addition to the HIV-1 receptor, CD4. While CD4 is required for HIV-1 attachment, the accessory molecules are required for the membrane fusion step of entry. These accessory molecules are generally expressed only on human cells, so HIV-1 does not infect non-human CD4 cells (3-6) . Moreover it is possible to complement non-human CD4" cells by fusing them (using polyethylene glycol) with CD4 " human cells, resulting in a heterokaryon which is a competent target for HIV-1 envelope-mediated membrane fusion (7,8) . These studies have been performed using laboratory-adapted T lymphotropic strains of the virus. In some cases, it appears that fusion accessory molecules are found on a subset of human CD4' cells and are required for infection by HIV-1 isolates with particular tropisms . For example, macrophage-tropic primary strains of HIV-l such as HIV-1 JR . FL may have different requirements for accessory molecules compared with laboratory-adapted T lymphotropic strains such as HIV-l^. This phenomenon may explain differences in tropism between HIV-l strains. The current invention comprises a series of new therapeutics for HIV-l infection. It was demonstrated for the first time that chemokines act at the fusion step of HIV-l entry and specifically inhibit membrane fusion mediated by the envelope glycoprotein of primary macrophage-tropic primary viral isolates, not laboratory-adapted T lymphotrophic strains of the virus. Primary macrophage-tropic isolates of the virus are of particular importance since they are the strains usually involved in virus transmission, and may have particular importance in the pathogenesis of HIV-l infection. These results were obtained using a resonance energy transfer (RET) assay of HIV-l envelope-mediated membrane fusion. Moreover, this assay is used to identify non-chemokines, including fragments of chemokines and modified chemokines, that inhibit HIV-l envelope glycoprotein-mediated membrane fusion and thereby neutralize the virus, yet do not induce an inflammatory response. Summary of the Invention This invention provides a method for inhibiting fusion of HIV-l to CD4 + cells which comprises contacting CD4 * cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-l to the CD4 + cells is inhibited. This invention also provides a method for inhibiting HIV-l infection of CD4' cells which comprises contacting CD4 + cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-l to the CD4 + cells is inhibited, thereby inhibiting the HIV-l infection. This invention further provides non-chemokine agents capable of binding to the chemokine receptor and inhibiting fusion of HIV-l to CD4 + cells. This invention provides an agent which is capable of binding to fusin and inhibiting infection. In an embodiment, the agent is an oligopeptide . In another embodiment, the agent is an polypeptide. In still another embodiment, the agent is an antibody or a portion of an antibody. In a separate embodiment, the agent is a nonypeptidyl agent. In addition, this invention provides pharmaceutical compositions comprising an amount of the above non-chemokine agents or agents capable of binding to fusin effective to inhibit fusion of HIV-l to CD4 * cells and a pharmaceutically acceptable carrier. This invention provides a composition of matter capable of binding to the chemokine receptor and inhibiting fusion of HIV-l to CD4 + cells comprising a non-chemokine agent linked to a ligand capable of binding to a cell surface receptor of the CD4 * cells other than the chemokine receptor such that the binding of the non-chemokine agent to the chemokine receptor does not prevent the binding of the ligand to the other receptor. This invention also provides a pharmaceutical composition comprising an amount of the above-described composition of matter effective to inhibit fusion of HIV-l to CD4 + cells and a pharmaceutically acceptable carrier. This invention provides a composition of matter capable of binding to tne chemokine receptor and inhibiting fusion of HIV-l to CD4 cells comprising a non-chemokme agent linked to a compound capable of increasing the m vivo half-life of the non-chemokme agent. This invention also provides a pharmaceutical composition comprising an amount of a composition of matter comprising a non-chemokme agent linked to a compound capable of increasing the m vivo half-life of the non-chemokme agent effective to inhibit fusion of HIV-l to CD4 + cells and a pharmaceutically acceptable carrier. This invention provide methods for reducing the likelihood of HIV-l infection a subject comprising administering an above-described pharmaceutical composition to the subject. This invention also provides methods for treating HIV-l infection m a subject comprising administering an above- described pharmaceutical composition to the subject. This invention also provides methods for determining whether a non-chemokme agent is capable of inhibiting the fusion of HIV-l to a CD4 + cell which comprise, (a) contacting (I) a CD4 T cell which is labeled with a first dye and (n) a cell expressing tne HIV-l envelope glycoprotein on its surface which is labeled with a second dye, in the presence of an excess of the agent under conditions permitting the fusion of the CD4" cell to the cell expressing the HIV-l envelope glycoprotein on its surface in the absence of the agent, the first and second dyes being selected so as to allow resonance energy transfer between the dyes; (b) exposing the product of step (a) to conditions which would result in resonance energy transfer if fusion has occurred; and (c) determining whether there is a reduction of resonance energy transfer, when compared with the resonance energy transfer in the absence of the agent , a decrease in transfer indicating that the agent is capable of inhibiting fusion of HIV-l to CD4 + cells. Brief Description of the Figures Figure 1. Membrane fusion mediated by the HIV-1^.^ envelope glycoprotein is inhibited by RANTES, MlP-lor and MIP-l/S. %RET resulting from the fusion of PM1 cells and HeLa-env JR _ FL (■) or (♦) was measured in the presence and absence of recombinant human chemokines at a range of concentrations: RANTES (80 - 2.5 ng/ml) , MlP-lα (400 - 12.5 ng/ml) and MIP-10 (200 - 6.25 ng/ml) , as indicated. Chemokines were added simultaneously with the cells at the initiation of a four hour incubation. Data are representative of more than three independent experiments which were run in duplicate. The percent inhibition of RET is defined as follows: % Inhibition = 100 . [(Max RET - Min RET) - (Exp RET- Min RET) ] / (Max RET - Min RET) where Max RET is the %RET value obtained at four hours with HeLa-env cells and CD4-expressing cells in the absence of an inhibitory compound; Exp RET is the %RET value obtained for the same cell combination in the presence of an inhibitory compound and Min RET is the background %RET value obtained using HeLa cells in place of HeLa envelope-expressing cells. Figure 2. CD4:HIV-l gpl20 binding in the presence of human chemokines. The binding of soluble human CD4 to HIV-1^ and HIV-1 JR . FL gpl20 was determined in an ELISA assay in the presence and absence of the monoclonal antibody OKT4A or recombinant human chemokines at a range of concentrations, identical to those used in the RET inhibition studies of Figure 1: OKT4A (62 - 0.3 nM) , RANTES (10.3 - 0.3 nM) , MlP-lα (53.3 - 2.9 nM) , and MIP-lS (25.6 - 0.8 nM) . Inhibitors were added simultaneously with biotinylated HIV-l gpl20 to soluble CD4 coated microtiter plates (Dynatech Laboratories, Inc., Chantilly, VA) . Following a two hour incubation at room temperature and extensive washing, an incubation with streptavidin-horseradish peroxidase was performed for one hour at room temperature. Following additional washes, substrate was added and the OD at 492 nm determined in an ELISA plate reader. Data are representative of two independent experiments which were run in quadruplicate. Figure 3. Specificity, time course and stage of β-chemokine inhibition of HIV-l replication. (a) PM1 cells (1 xlO 6 ) were preincubated with RANTES + MIP- lα + MIP-lS (R/Mα/Mβ; lOOng/ml of each) for 24h (-24h) or 2h (-2h) , then washed twice with phosphate buffered saline (PBS) . HIV- 1 (BaL env-complemented) virus (50ng of p24 ; see legend to Table 1) was added for 2h, then the cells were washed and incubated for 48h before measurement of luciferase activity in cell lysates as described previously (10,11) . Alternatively, virus and R/Mα/Mβ were added simultaneously to cells, and at the indicated time points (lh, 3h, etc) the cells were washed twice in PBS, resuspended in culture medium and incubated for 48h prior to luciferase assay. Time 0 represents the positive control, to which no β-chemokines were added. +2h represents the mixture of virus with cells for 2h prior to washing twice in PBS, addition of R/Mα/Mβ and continuation of the culture for a further 48h before luciferase assay. (b) PM1 cells (lxlO 6 ) were infected with HIV-l (500pg p24) grown in CEM cells (NL4/3; lanes 1-4) or macrophages (ADA; lanes 5-8) , in the presence of 500ng/ml of RANTES (lanes 1 and 5) or MIP-lβ (lanes 2 and 6) , or with no β-chemokine (lanes 4 and 8) . Lanes 3 and 7 are negative controls (no virus) . All viral stocks used for the PCR assay were treated with DNAse for 30 min at 37°C, and tested for DNA contamination before use. After 2h, the cells were washed and resuspended in medium containing the same β-chemokines for a further 8h. DNA was then extracted from infected cells using a DNA/RNA isolation kit (US Biochemicals) . First round nested PCR was pe rf ormed wi t h pr ime r s : U3 + , 5' -CAAGGCTACTTCCCTGATTGGCAGAACTACACACCAGG-3 ' (SEQ ID NO:l) preGag, 5' -AGCAAGCCGAGTCCTGCGTCGAGAG-3 ' (SEQ ID NO:2) and the second round with primers: LTR-test, 5' -GGGACTTTCCGCTGGGGACTTTC 3' (SEQ ID NO :3) LRC2 , 5' -CCTGTTCGGGCGCCACTGCTAGAGATTTTCCAC 3' (SEQ ID N0:4) in a Perkin Elmer 2400 cycler with the following amplification cycles: 94°C for 5 min, 35 cycles of 94°C for 30s, 55°C for 30s, 72°C for 30s, 72 C for 7 min. M indicates lkb DNA ladder; 1, 10, 100, 1000 indicate number of reference plasmid (pAD8) copies. The assay can detect 100 copies of reverse transcripts. Figure 4: HIV-l env-mediated membrane fusion of cells transiently expressing C-C CKR-5. Membrane fusion mediated by β-chemokine receptors expressed in HeLa cells was demonstrated as follows: Cells were transfected with control plasmid pcDNA3.1 or plasmid pcDNA3.1 -CKR constructs using lipofectin (Gibco BRL) . The pcDNA3.1 plasmid carries a T7-polymerase promoter and transient expression of β-chemokine receptors was boosted by infecting cells with IxlO 7 pfu of vaccinia encoding the T7-polymerase (vFT7.3) 4h post-lipofection (9) . Cells were then cultured overnight in R18-containing media and were tested for their ability to fuse with HeLa-JR-FL cells (filled columns) or HeLa-BRU cells (hatched column) in the RET assay. The %RET with control HeLa cells was between 3% and 4% irrespective of the transfected plasmid. Figure 5 Membrane fusion mediated by the HIV^- envelope glycoprotein is inhibited by SDF-1. % RET resulting from the fusion of PM1 cells and HeLa-env JR _ FL or HeLa-env^ cells (as indicated on the graph) was measured in the presence of recombinant SDF-lα (Gryphon Science, San Francisco) at the indicated concentrations. Experimental method as described in the legend to Fig. l. Detailed Description of the Invention This invention provides a method for inhibiting fusion of HIV-l to CD4 + cells which comprises contacting CD4 * cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-l to the CD4 + cells is inhibited. This invention also provides a method for inhibiting HIV-l infection of CD4 + cells which comprises contacting CD4 + cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-l to the CD4 + cells is inhibited, thereby inhibiting the HIV-l infection. In this invention, a chemokine means RANTES, MIP-1-α, MIP-1- β or another chemokine which blocks HIV-l infection. A chemokine receptor means a receptor capable of binding RANTES, MIP-1-α, MIP-1- / 3 or another chemokine which blocks HIV-l infection. Throughout this application, the receptor "fusin" is also named CXCR4 and the chemokine receptor C-C CKR5 is also named CCR5. The HIV-l used in this application unless specified will mean clinical or primary or field isolates or HIV-l viruses which maintain their clinical characteristics. The HIV-l clinical isolates may be passaged in primary peripheral blood mononuclear cells. The HIV-l clinical isolates may be macrophage-trophic. The non-chemokine agents of this invention are capable of binding to chemokine receptors and inhibiting fusion of HIV- 1 to CD4" cells. The non-chemokine agents include, but are not limited to, chemokine fragments and chemokine derivatives and analogues, but do not include naturally occurring chemokines. The non-chemokine agents include multimeric forms of the chemokine fragments and chemokine derivatives and analogues or fusion molecules which contain chemokine fragments, derivatives and analogues linked to other molecules. In an embodiment of this invention, the non-chemokine agent is an oligopeptide. In another embodiment, the non- chemokine agent is a polypeptide. In still another embodiment, the non-chemokine agent is an antibody or a portion thereof. Antibodies against the chemokine receptor may easily be generated by routine experiments. It is also within the level of ordinary skill to synthesize fragments of the antibody capable of binding to the chemokine receptor. In a further embodiment, the non-chemokine agent is a nonpeptidyl agent. Non-chemokine agents which are purely peptidyl in composition can be either chemically synthesized by solid- phase methods (Merrifield, 1966) or produced using recombinant technology in either prokaryotic or eukaryotic systems. The synthetic and recombinant methods are well known in the art . Non-chemokine agents which contain biotin or other nonpeptidyl groups can be prepared by chemical modification of synthetic or recombinant chemokines or non-chemokine agents. One chemical modification method involves periodate oxidation of the 2-amino alcohol present on chemokines or non-chemokine agents possessing serine or threonine as their N-terminal amino acid (Geophegan and Stroh, 1992) . The resulting aldehyde group can be used to link peptidyl or non-peptidyl groups to the oxidized chemokine or non- chemokine agent by reductive amination, hydrazine, or other chemistries well known to those skilled in the art. As used herein, a N-terminus of a protein should mean the terminus of the protein after it has been processed. In case of a secretory protein which contains a cleavable signal sequence, the N-terminus of a secretory protein should be the terminus after the cleavage of a signal peptide. This invention provides a method of identifying these non- chemokine agents. One way of identifying such agents, including non-peptidyl agents, that bind to a chemokine receptor and inhibit fusion of HIV-l to CD4 + cells is to use the following assay: 1) Incubate soluble CD4 with biotinylated gpl20 from HIV-1 JR _ FL or HIV-l^; 2) Incubate this complex with CCR5 or CXCR4-expressing cells (for HIV- ! JR - F or HIV-1 i A i gpl20s, respectively) that do not express CD4 , in the presence of absence of a candidate inhibitor; 3) Wash and then incubate with streptavidin-phycoerythrin; and 4) Wash and then measure the amount of bound gpl20 using a flow cytometer or fluorometer and calculate the degree of inhibition of binding by the inhibitor. Alternative methods to detect bound gpl20 can also be used in place of the biotinylated gpl20-streptavidin- phycoerythrin method described above. For example, peroxidase-conjugated gpl20 could be used place of the biotinylated gpl20 and binding detected using an appropriate colorimetric substrate for peroxidase, with a spectrometric readout . This invention further provides the non-chemokine agents identified by the above methods. This invention provides a non-chemokine agent capable of binding to the chemokine receptor and inhibiting fusion of HIV-l to CD4 * cells. In an embodiment, the non-chemokine is a polypeptide. In a further embodiment, this polypeptide is a fragment of the chemokine RANTES (Gong et al . , 1996) . In a still further embodiment, the polypeptide may also comprise the RANTES sequence with deletion of the N-terminal amino acids of said sequence. The deletion may be the first eight N-terminal amino acids of the RANTES sequence (SEQ ID NO: 5) . In a separate embodiment, the polypeptide may comprise the MIP-lβ sequence with deletion of the N-terminal amino acids of said sequence. The deletion may be the first seven, eight, nine or ten N-terminal amino acids of the MIP-lβ sequence. In another embodiment of non-chemokine agent, the polypeptide comprises the MIP-lβ sequence with the N- terminal sequence modified by addition of an amino acid or oligopeptide . In a separate embodiment, the polypeptide comprises the MIP-lβ sequence with the N-terminal sequence modified by removing the N-terminal alanine and replaced it by serine or threonine and additional amino acid or oligopeptide or nonpeptidyl moiety. In a further embodiment, the additional amino acid is methionine. As described infra in the section of Experimental Details, a cofactor for HIV-l fusion and entry was identified and designated "fusin" (Feng et al . , 1996) . This invention provides an agent which is capable of binding to fusin and inhibiting infection. In an embodiment, the agent is an oligopeptide. In another embodiment, the agent is an polypeptide. In a further embodiment, the polypeptide comprises SDF-1 with deletion of the N-terminal amino acids of said sequence. The deletion may be the first six, seven, eight, or nine N-terminal amino acids of the SDF-1 sequence. This invention also provides the above non-chemokine agent, wherein the polypeptide comprises SDF-1 sequence with the N- terminal sequence modified to produce antagonistic effect to SDF-1. One modification is to replace the N-terminal glycine of SDF-1 by serine and derivatized with biotin. Another modification is to replace the N-terminal glycine of SDF-1 by serine and derivatized with methionine . A further modification is to add the N-terminus of SDF-1 with a methionine before the terminal glycine . In still another embodiment, the agent is an antibody or a portion of an antibody. In a separate embodiment, the agent is a nonpeptidyl agent . The agents capable of binding to fusin may be identified by screening different compounds for their capability to bind to fusin in vitro. A suitable method has been described by Fowlkes, et al . (1994) , international application number: PCT/US94/03143 , international publication number: WO 94/23025, the content of which is incorporated by reference into this application. Briefly, yeast cells having a pheromone system are engineered to express a heterologous surrogate of a yeast pheromone system protein. The surrogate incorporates fusin and under some conditions performs in the pheromone system of the yeast cell a function naturally performed by the corresponding yeast pheromone system protein. Such yeast cells are also engineered to express a library of peptides whereby a yeast cell containing a peptide which binds fusin exhibits modulation of the interaction of surrogate yeast pheromone system protein with the yeast pheromone system and this modulation is a selectable or screenable event. Similar approaches may be used to identify agents capable of binding to both fusin and the chemokine receptor C-C CKR-5. This invention also provides pharmaceutical compositions comprising an amount of such non-chemokine agents or agents capable of binding to fusin effective to inhibit fusion of HIV-l to CD4 + cells and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known to those skilled in the art. Such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, chelating agents, inert gases and the like. This invention provides a composition of matter capable of binding to the chemokine receptor and inhibiting fusion of HIV-l to CD4 + cells comprising a non-chemokine agent linked to a ligand capable of binding to a cell surface receptor of the CD4 T cells other than the chemokine receptor such that the binding of the non-chemokine agent to the chemokine receptor does not prevent the binding of the ligand to the other receptor. In an embodiment, the cell surface receptor is CD4. In another embodiment, the ligand is an antibody or a portion of an antibody. This invention also provides a pharmaceutical composition comprising an amount of an above-described composition of matter effective to inhibit fusion of HIV-l to CD4 + cells and a pharmaceutically acceptable carrier. This invention provides a composition of matter capable of binding to the chemokine receptor and inhibiting fusion of HIV-l to CD4 " cells comprising a non-chemokine agent linked to a compound capable of increasing the in vivo half-life of the non-chemokine agent. In an embodiment, the compound is polyethylene glycol . This invention also provides a pharmaceutical composition comprising an amount of a composition of matter comprising a non-chemokine agent linked to a compound capable of increasing the in vivo half-life of the non-chemokine agent effective to inhibit fusion of HIV-l to CD4 + cells and a pharmaceutically acceptable carrier. This invention provide methods for reducing likelihood of HIV-l infection in a subject comprising administering the above-described pharmaceutical compositions to the subject. This invention also provides methods for treating HIV-l infection in a subject comprising administering the above- described pharmaceutical compositions to the subject. This invention also provides methods for determining whether a non-chemokine agent is capable of inhibiting the fusion of HIV-l to a CD4 * cell which comprise: (a) contacting (i) a CD4 * cell which is labeled with a first dye and (ii) a cell expressing the HIV-l envelope glycoprotein on its surface which is labeled with a second dye, in the presence of an excess of the agent under conditions permitting the fusion of the CD4 + cell to the cell expressing the HIV-l envelope glycoprotein on its surface in the absence of the agent, the first and second dyes being selected so as to allow resonance energy transfer between the dyes; (b) exposing the product of step (a) to conditions which would result in resonance energy transfer if fusion has occurred; and (c) determining whether there is a reduction of resonance energy transfer, when compared with the resonance energy transfer in the absence of the agent, a decrease in transfer indicating that the agent is capable of inhibiting fusion of HIV-l to CD4- cells. HIV-l only fuses with appropriate CD4 + cells. For example, laboratory-adapted T lymphotropic HIV-l strains fuse with most CD4 + human cells. Clinical HIV-l isolates do not fuse with most transformed CD4 * human cell lines but do fuse with human primary CD4 + cells such as CD4 + T lymphocytes and macrophages. Routine experiments may be easily performed to determine whether the CD4 * cell is appropriate for the above fusion assay. As described in this invention, HIV-l membrane fusion is monitored by a resonance energy transfer assay. The assay was described in the International Application Number, PCT/US94/14561, filed December 16, 1994 with International Publication Number WO 95/16789. This assay is further elaborated in a United States co-pending application no. 08/475,515, filed June 7, 1995. The contents of these applications are hereby incorporated by reference into this application. In an embodiment of the above method, the non-chemokine agent is an oligopeptide. In another embodiment, the non- chemokine agent is a polypeptide. In still another embodiment, the agent is an antibody or a portion thereof. In a further embodiment, the non-chemokine agent is a nonpeptidyl agent. In a separate embodiment, the CD4 + cell is a PM1 cell. In another embodiment, the cell expressing the HIV-l envelope glycoprotein is a HeLa cell expressing HIV-1 JR _ FL gpl20/gp41. This invention will be better understood by reference to the Experimental Details which follow, but those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention as described more fully in the claims which follow thereafter. Experimental Details FIRST SERIES OF EXPERIMENTS 1) Chemokines inhibit fusion mediated bv the envelope glycoprotein from a macrophage-tropic primary isolate of HIV-l but not from a laboratory-adapted T- lymphotrophic strain of the virus The chemokines RANTES, MlP-lα and MIP-l / S were obtained from R & D systems (Minneapolis, MN) . They were tested in the RET assay for ability to inhibit fusion between HeLa-env JR _ FL cells (expressing gpl20/gp41 from the macrophage tropic isolate HIV-1 JR _ FL ) and PM1 cells, or for inhibition of fusion between HeLa-env ul cells (expressing gpl20/gp41 from the laboratory-adapted strain HIV-l^) and various CD4' T lymphocyte cell lines. As shown in Figure 1, all three chemokines inhibited fusion mediated by the macrophage tropic virus envelope glycoprotein, but not that mediated by the laboratory-adapted strain envelope glycoprotein. The ability of the chemokines to block the interaction between CD4 and HIV-l gpl20 which occurs at virus attachment was then tested. It was found that the chemokines did not inhibit this interaction (Figure 2) , demonstrating that their blockade of HIV-l envelope glycoprotein-mediated membrane fusion occurs at the membrane fusion event itself, rather than the initial CD4-gpl20 interaction which precedes fusion. 2) Non-chemokine peptides and derivatives that inhibit HIV-l fusion The non-chemokines include chemokine fragments and chemokine derivatives that are tested in the RET assay to determine which are active in inhibiting HIV-l membrane fusion. Particular attention is focused on fragments or derivatives that inhibit HIV-l fusion but do not activate leukocyte responses. These non-chemokines include: a) N-terminal derivatives of the chemokines. Addition of residues to the N-terminus of chemokines inhibits the function of these proteins without significantly reducing their ability to bind chemokine receptors. For example, Met-RANTES (RANTES with an N-terminal methionine) has been shown to be a powerful antagonist of native RANTES and iε unable to induce chemotaxis or calcium mobilization in certain systems. The mechanism of antagonism appears to be competition for receptor binding (9) . Similar results were found using other derivatives of the N terminus of RANTES (9) and also by N-terminal modification of other chemokines, such as IL-8 (a member of the C-X-C chemokines) (10) . The current invention includes Met-RANTES and other chemokines derivatised by the addition of methionine, or other residues, to the N-terminus so that they inhibit fusion mediated by the envelope glycoprotein of HIV-1 JR _ FL , and inhibit infection by many isolates of HIV-l, yet do not activate the inflammatory response. b) Chemokines with N-terminal amino acids deleted: Chemokine antagonists have been generated by deleting amino acids in the N-terminal region. For example, deletion of up to 8 amino acids at the N-terminus of the chemokine MCP-1 (a member of the C-C chemokine group) , ablated the bioactivity of the protein while allowing it to retain chemokine receptor binding and the ability to inhibit activity of native MCP-1 (11,12) . The current invention includes N-terminal deletants of RANTES, MlP-lα and MIP-1/3, lacking the biological activity of the native proteins, which inhibit HIV-l fusion and HIV-l infection. c) Other peptides: A series of overlapping peptides (e.g. of 20-67 residues) from all regions of RANTES, MIP-lα and MIP-1/3 are screened by the same approaches to identify peptides which inhibit HIV-l fusion most potently without activating leukocytes. Activation of leukocyte responses is measured following routine procedures (9, 10, 11, 12) . 3) Cloning the chemokine receptors Chemokine receptors required for HIV-l fusion are cloned by the following strategy. First a cDNA library is made in a mammalian expression vector (e.g. pcDNA3.1 from Invitrogen Corp. San Diego, CA) using mRNA prepared from the PM1 cell line or CD4 * T-lymphocytes or macrophages. Degenerate oligonucleotide probes are used to identify members of the cDNA library encoding members of the chemokine receptor family, for example following previously published methods (2) . The vectors containing chemokine receptor cDNAs are then individually expressed in one of several mammalian cell lines which express human CD4 but do not fuse with HeLa-env JR . FL cells (e.g. HeLa-CD4, CHO-CD4 or COS-CD4) or HeLa-env^ ! cells (e.g. CHO-CD4 or COS-CD4) . Following analysis in the RET assay, clones which gain the ability to fuse with HeLa-env JR . FL or HeLa-env,^ are identified and the coding sequences recovered, for example by PCR amplification, following procedures well known to those skilled in the art. DNA sequencing is then performed to determine whether the cDNA recovered encodes a known chemokine receptor. Following expression of the receptor, monoclonal and polyclonal antibodies are prepared and tested for ability to inhibit infection by a panel of HIV-l isolates. References of the First Series of Experiments 1. Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C, Lusso, P. 1995. Science . 270:1811- 1815. 2. Raport, C. J., Schweickart, V. L. , Chantry, D., Eddy Jr., R. L., Shows, T. B., Godiska, R. , Gray, P. W. 1996. Journal of Leukocyte Biology. 59: 18-23. 3. Maddon PJ., Dalgleish AG. , McDougal JS. , Clapham PR., Weiss RA. , Axel R. 1986. Cell . 47:333-348. 4. Ashorn PA., Berger EA. , Moss B. 1990. J. Virol . 64:2149-2156. 5. Clapham PR., Blanc D., Weiss RA. 1991. Virology. 181:703-715. 6. Harrington RD. , Geballe AP. 1993. J. Virol . 67:5939-5947. 7. Broder CC. , Dimitrov DS. , Blu enthal R., Berger EA. 1993. Virology. 193:483-491. 8. Dragic T., Charneau P., Clavel F., Alizon M. 1992. J. Virol . 66:4794-4802. 9. Wells, T. N. , Power, C. A., Lusti-Narasimhan, M. , Hoogewerf, A. J. , Cooke, R. M., Chung, C. W., Peitsch, M. C. , Proudfoot, A. E. 1996. Journal of Leukocyte Biology. 59:53-60. 10. Moser, B., Dewald, B., Barella, L., Schumacher, C, Baggiolini, M., Clark-Lewis, I. 1993. Journal of Biological Chemistry. 268:7125-7128. 11. Gong, J. H., Clark-Lewis, I. 1995. J. Exp . Med. 181:631-640. 12. Zhang, Y. J., Rutledge, B. J. , Rollins, B. J. 1994. Journal of Biological Chemistry. 269:15918-15924. 13. Merrifield, R.B. (1963) J. Am. Chem . Soc . 85: 2149-2154. 14. Goeghegan, K.F. Stroh, J.F. (1992) Bioconjugate Chem . 3: 138-146. SECOND SERIES OF EXPERIMENTS The replication of primary, non-syncytium-inducing (NSI) HIV-l isolates in CD4 + T-cells is inhibited by the C-C β-chemokines MlP-lα, MIP-lβ and RANTES (1,2) , but T-cell line-adapted (TCLA) or syncytium-inducing (SI) primary strains are insensitive (2,3) . The β-chemokines are small (8kDa) , related proteins active on cells of the lymphoid and monocyte lineage (4-8) . Their receptors are members of the 7-membrane-spanning, G-protein-linked superfamily, one of which (the LESTR orphan receptor) has been identified as the second receptor for TCLA HIV-l strains, and is now designated fusin (9) . Fusin is not known to be a β-chemokine receptor (7-9) . To study how β-chemokines inhibit HIV-l replication, a virus entry assay based on single-cycle infection by an env-deficient virus, NL4/3Δenv (which also carries the luciferase reporter gene) , complemented by envelope glycoproteins expressed in trans was used (10,11) . Various env-complemented viruses were tested in PM1 cells, a variant of HUT-78 that has the unique ability to support replication of primary and TCLA HIV-l strains, allowing comparison of envelope glycoprotein functions against a common cellular background (2,12) . MIP-lα, MIP-lβ and RANTES are most active against HIV-l in combination (2,3) , and strongly inhibited infection of PM1 cells by complemented viruses whose envelopes are derived from the NSI primary strains ADA and BaL (Table la) . Table 1: Inhibition of HIV-l entry in PM1 cells and CD4* T-cells by β-chemokines Table 1 legend: PM1 cells were cultured as described by Lusso et al (12) . Ficoll/hypaque-isolated PBMC from laboratory workers (LW) stimulated with PHA for 72h before depletion of CD8 + Lymphocytes with anti- CD8 immunomagnetic beads (DYNAL, Great Neck, NY). CD4+ Lymphocytes were maintained in culture medium containing interleukin-2 (lOOU/ l; Hofmann LaRoche , Nutley, NJ) , as described previously (3). Target cells (1-2x10 s ) were infected with supernatants (10-50ng of HIV-l p2 4 ) from 293-cells co- transfected with an 0 NL4/3Aenv-luciferase vector and a HIV-l env- express ing vector (10,11) . β-Chemokines (R & D Systems, Minneapolis) were added to the target cells simultaneously with virus, at the final concentrations (ng/ml) indicated in parentheses in the first column. The β- chemokine concentration range was selected based on prior s tudies (2 , 3 ) . After 2h, the cells were washed twice wi th PBS, resuspended in β- chemokine - containing media and main tained for 48 - 96h . Luciferase activi ty in cell lysa tes was measured as described previously (10 , 11 ) . The values indica ted represent luciferase activi ty (cpm) /ng p24/mg protein, expressed rela tive to tha t in virus- control cul tures lacking β- chemokines (100%) , and are the means of duplica te or sextuplica te determina tions . nd, not done . R/M /Mβ, RANTES + MlP- lα + MlP-lβ . RANTES and MIP-lβ were strongly active when added individually, while other β-chemokines - MlP-lα, MCP-1, MCP-2 and MCP-3 (refs. 13-15) - were weaker inhibitors (Table la) . However, MlP-lα, MIP-lβ and RANTES, in combination, did not inhibit infection of PM1 cells by the TCLA strains NL4/3 and HxB2, or by the amphotropic murine leukemia virus (MuLV-Ampho) pseudotype (Table la) . Thus, phenotypic characteristics of the HIV-l envelope glycoproteins influence their sensitivity to β-chemokines in a virus entry assay. The env-complementation assay was used to assess HIV-l entry intc CD4+ T-cells from two control individuals (LW4 and LW5) . MlP-lα, MIP-lβ and RANTES strongly inhibited infection by the NSI primary strain JR-FL infection of LW4' s and LW5' s CD4 + T-cells, and weakly reduced HxB2 infection of LW cells (Table lb) , suggesting that there may be some overlap in receptor usage on activated CD4 + T-cells by different virus strains. BaL env-mediated replication in normal PBL was also inhibited by MIP-lα, MIP-lβ and RANTES, albeit with significant inter-donor variation in sensitivity (data not shown) . It was determined when β-chemokines inhibited HIV-l replication by showing that complete inhibition of infection of PM1 cells required the continuous presence of β -chemokines for up to 5h after addition of ADA or BaL env-complemented virus (Fig.3a) . Pre-treatment of the cells with β-chemokines for 2h or 24h prior to infection had no inhibitory effect if the cells were subsequently washed before virus addition. Furthermore, adding β-chemokines 2h after virus only minimally affected virus entry (Fig.3a) . A PCR-based assay was next used to detect HIV-l early DNA reverse transcripts in PM1 cells after lOh of infection; reverse transcription of ADA, but not of NL4/3, could not be detected in the presence of MIP-lβ and RANTES (Fig.3b) . Thus, inhibition by β-chemokines requires their presence during at least one of the early stages of HIV-l replication: virus attachment, fusion and early reverse transcription. As described in part in the First Series of Experiments, these sites of action were discriminated, first by testing whether β-chemokines inhibited binding of JR-FL or BRU (LAI) gpl20 to soluble CD4, or of tetrameric CD4-IgG2 binding to HeLa-JR-FL cells expressing oligomeric envelope glycoproteinε (17) . No inhibition by any of the β-chemokines was found in either assay, whereas the OKT4a CD4-MAb was strongly inhibitory in both (Fig. 2 and data not shown) . Thus, β-chemokines inhibit a step after CD4 binding, when conformational changes in the envelope glycoproteins lead to fusion of the viral and cellular membranes (18) . Cell-cell membrane fusion is also induced by the gpl20-CD4 interaction, and can be monitored directly by resonance energy transfer (RET) between fluorescent dyes incorporated into cell membranes (17) . In the RET assay, 0KT4a completely inhibits membrane fusion of PM1 cells with HeLa cells expressing the envelope glycoproteins of either JR-FL (HeLa-JR-FL, the same cell line referred to above as HeLa- env. or BRU (HeLa-BRU, the same cell line referred to above as HeLa-env^ j ) , confirming the specificity of the process (17) . RANTES, MlP-lβ (and to a lesser extent, MlP-lα) strongly inhibited membrane fusion of HeLa-JR-FL cells with PMl cells, whereas fusion between PMl cells and HeLa-BRU cells was insensitive to these β-chemokines (Fig. 1 and Table 2a) . Table 2:Effect of β-chemokines on HIV-l envelope glycoprotein-mediated membrane fusion measured using the RET assay Table 2 l egend : CD4* target cells (mi togen-activated CD4 * lymphocytes or PMl 0 cells) were labeled wi th octadecyl rhodamine (Mol ecular Probes, Eugene, OR) , and HeLa -JR-FL cells , HeLa -BRU cells (or control HeLa cells, not shown) were labeled wi th octadecyl fluorescein (Molecular Probes) , overnight a t 37°C. Equal numbers of labeled target cells and env- expressing 5 cells were mixed in 96-well pla tes and β- chemokines (or CD4 MAb OKT4a) were added at the final concen tra tions (ng/ml ) indica ted in parentheses in the first column . Fluorescence emission values were determined 4h after cell mixing (17) . If cell fusion occurs, the dyes are closely associated in the conjoined membrane such that excitation of fluorescein at 450nm results in resonance energy transfer (RET) and emission by rhodamine at 590nm. Percentage fusion is defined as equal to 100 x [(Exp RET - Min RET) / (Max RET - Min RET)] , where Max RET = %RET obtained when HeLa- Env and CD4* cells are mixed, Exp RET = %RET obtained when HeLa-Env and CD4 * cells are mixed in the presence of fusion- inhibitory compounds, and Min RET = %RET obtained when HeLa cells (lacking HIV-l envelope glycoproteins) and CD4' cells are mixed. The %RET value is defined by a calculation described elsewhere (17 } , and each is the mean of triplicate determinations. These values were, for HeLa-JR-FL and HeLa-BRU cells respectively: PMl cells 11.5%, 10.5%; LW5 CD4 * cells, 6.0%, 10.5%; R/M /Mβ, RANTES + MI P- lot + MIP-lβ. Similar results were obtained with primary CD4 + T-cells from LW5 (Table 2b) , although higher concentrations of β-chemokines were required to inhibit membrane fusion in the primary cells than in PMl cells. Thus, the actions of the β-chemokineε are not restricted to the PMl cell line. The RET assay demonstrates that β-chemokines interfere with env-mediated membrane fusion. The simplest explanation of these results is that the binding of certain β-chemokines to their receptor (s) prevents, directly or otherwise, the fusion of HIV-l with CD4 + T-cells. It has been known for a decade that HIV-l requires a second receptor for entry into CD4 + cells (19-21) . This function is supplied, for TCLA strains, by fusin (9) . Several receptors for MlP-lα, MlP-lβ and RANTES have been identified (6,7) , and β-chemokines exhibit considerable cross-reactivity in receptor usage (4-8) . However, C-C CKR-1 and, especially, C-C CKR-5 were identified as the most likely candidates, based on tissue expression patterns and their abilities to bind MlP-lα, MlP-lβ and RANTES (4,7,8,15,22) . C-C CKR-1, C-C CKR-5 and LESTR are each expressed at the mRNA level in PMl cells and primary macrophages (data not shown) . These and other β-chemokine receptors were therefore PCR-amplified, cloned and expressed. The expression of C-C CKR-5 in HeLa-CD4 (human) , COS-CD4 (simian) and 3T3-CD4 (murine) cells rendered each of them readily infectible by the primary, NSI strains ADA and BaL in the env-complementation assay of HIV-l entry (Table 3) . Table 3: C-C CKR-5 expression permits infection of CD4-expressing cells by primary, NSI HIV-l strains tn x m m H 3 m Tabl e 3 1 egend : Chemokine receptor genes C-C CKR-1, C-C CKR-2a, C-C CKR-3, C-C CKR-4 and C-C CKR-5 have no introns (4-8, 15,22) and were isolated by PCR performed directly on a human genomic DNA pool derived from the PBMC of seven healthy donors. Oligonucleotides overlapping the ATG and the stop codons and containing BamHI and Xhol restriction sites for directional cloning into the pcDNA3.1 expression vector (Invitrogen Inc.) were used. LESTR (also known as fusin or HUMSTR) (4,9,24) was cloned by PCR performed directly on cDNA derived from PMl cells, using sequences derived from the NIH database. Listed below are the 5 ' and 3' primer pairs used in first (5-1 and 3-1) and second (5-2 and 3-2) round PCR amplification of the CKR genes directly from human genomic DNA, and of LESTR from PMl cDNA. Only a single set of primers was used to amplify CKR-5. LESTR: L/5-1 = AAG CTT GGA GAA CCA GCG GTT ACC ATG GAG GGG ATC (SEQ ID NO: 6) ; L/5-2 = GTC TGA GTC TGA GTC AAG CTT GGA GAA CCA (SEQ ID NO: 7) ; L/3-1 = CTC GAG CAT CTG TGT TAG CTG GAG TGA AAA CTT GAA GAC TC (SEQ ID NO: 8) ; L/3-2 = GTC TGA GTC TGA GTC CTC GAG CAT CTG TGT (SEQ ID NO: 9) ; CKR-1.-C1/5-1 = AAG CTT CAG AGA GAA GCC GGG ATG GAA ACT CC (SEQ ID NO: 10) ; Cl/5-2 = GTC TGA GTC TGA GTC AAG CTT CAG AGA GAA (SEQ ID NO: ID; Cl/3-1 = CTC GAG CTG AGT CAG AAC CCA GCA GAG AGT TC (SEQ ID NO: 12); Cl/3-2 = GTC TGA GTC TGA GTC CTC GAG CTG AGT CAG (SEQ ID NO: 13) ; CKR-2a:C2/5-l = AAG CTT CAG TAC ATC CAC AAC ATG CTG TCC AC (SEQ ID NO: 14) ; C2/5-2= GTC TGA GTC TGA GTC AAG CTT CAG TAC ATC (SEQ ID NO: 15) ; C2/3-1 = CTC GAG CCT CGT TTT ATA AAC CAG CCG AGA C (SEQ ID NO: 16); C2/3-2 = GTC TGA GTC TGA GTC CTC GAG CCT CGT TTT (SEQ ID NO: 17) ; CKR-3: C3/5-1 = AAG CTT CAG GGA GAA GTG AAA TGA CAA CC (SEQ ID NO: 18) ; C3/5-2= GTC TGA GTC TGA GTC AAG CTT CAG GGA GAA (SEQ ID NO: 19); C3/3-1 = CTC GAG CAG ACC TAA AAC ACA ATA GAG AGT TCC (SEQ ID NO: 20) ; C3/3-2 = GTC TGA GTC TGA GTC CTC GAG CAG ACC TAA (SEQ ID NO: 21) ; CKR-4: C4/5-1 = AAG CTT CTG TAG AGT TAA AAA ATG AAC CCC ACG G (SEQ ID NO: 22) ; C4/5-2 = GTC TGA GTC TGA GTC AAG CTT CTG TAG AGT (SEQ ID NO: 23) ; C4/3-1 = CTC GAG CCA TTT CAT TTT TCT ACA GGA CAG CAT C (SEQ ID NO: 24) ; C4/3-2 = GTC TGA GTC TGA GTC CTC GAG CCA TTT CAT (SEQ ID NO: 25) ; CKR-5: C5/5-12 = GTC TGA GTC TGA GTC AAG CTT AAC AAG ATG GAT TAT CAA (SEQ ID NO: 26); C5/3-12 = GTC TGA GTC TGA GTC CTC GAG TCC GTG TCA CAA GCC CAC (SEQ ID NO: 37) . The human CD4 -expressing cell lines HeLa-CD4 (P42), 3T3-CD4 (sc6) and COS-CD4 (Z28T1) (23) were transfected with the different pcDNA3.1-CKR constructs by the calcium phosphate method, then infected 48h later with different reporter viruses (200ng of HIV-l p24/10 e cells) in the presence or absence of β-chemokines (400ng/ml each of RANTES, MlP-lot and MIP-lβ) . Luciferase activity in cell lysates was measured 48h later (10,11) . β-Chemokine blocking data is only shown for C-C CKR-5, as infection mediated by the other C-C CKR genes was too weak for inhibi tion to be quantifiable . In PCR -based assays of HIV- l entry, a low level of entry of NL4/3 and ADA into C- C CKR -1 expressing cells (da ta not shown) was consistently observed . Neither LESTR nor C-C CKR-1, -2a, -3 or -4 could substitute for C-C CKR-5 in this assay. The expression of LESTR in COS-CD4 and 3T3-CD4 cells permitted HxB2 entry, and HxB2 readily entered untransfected (or control plasmid-transfected) HeLa-CD4 cells (Table 3) . Entry of BAL and ADA into all three C-C CKR-5-expressing cell lines was almost completely inhibited by the combination of MIP-lα, MIP-1S and RANTES, whereas HxB2 entry into LESTR-expressing cells was insensitive to β chemokines (Table 3) . These results suggest that C-C CKR-5 functions as a β-chemokine-sensitive second receptor for primary, NSI HIV-l strains. The second receptor function of C-C CKR-5 was confirmed in assays of env-mediated membrane fusion. When C-C CKR-5 was transiently expressed in COS and HeLa cell lines that permanently expressed human CD4, both cell lines fused strongly with HeLa cells expressing the JR-FL envelope glycoproteins, whereas no fusion occurred when control plasmids were used (data not shown) . Expression of LESTR instead of C-C CKR-5 did not permit either COS-CD4 or HeLa- CD4 cells to fuse with HeLa-JR-FL cells, but did allow fusion between C0S-CD4 cells and HeLa-BRU cells (data not shown) . The fusion capacity of β-chemokine receptors was also tested in the RET assay. The expression of C-C CKR-5, but not of C-C CKR-1, -2a, -3 or -4, permitted strong fusion between HeLa-CD4 cells and HeLa-JR-FL cells. The extent of fusion between HeLa-JR-FL cells and C-C CKR-5-expressing HeLa-CD4 cells was greater than the constitutive level of fusion between HeLa-BRU cells and HeLa-CD4 cells (Fig.4) . The fusion-conferring function of C-C CKR-5 for primary, NSI HIV-l strains has therefore been confirmed in two independent fusion assays. Experimental Discussion Together, the above results establish that MlP-lα, MIP-lβ and RANTES inhibit HIV-l infection at the entry stage, by interfering with the virus-cell fusion reaction subsequent to CD4 binding. It was also shown that C-C CKR-5 can serve as a second receptor for entry of primary NSI strains of HIV-l into CD4+ T-cells, and that the interaction of β-chemokines with C-C CKR-5 inhibits the HIV-l fusion reaction. References of the Second Series of Experiments 1. Levy, J.A., Mackewicz, C.E. & Barker, E. Immunol. Today 17, 217-224 (1996) . 2. Cocchi, F. et al . Science 270, 1811 -1815 (1995) . 3. Paxton,W.A. et al . Nat. Med. 2, 412-417 (1996) . 4. Neote,K., DiGregorio,D. , Mak,J.Y. , Horuk,R., & Schall,T.J. Cell 72, 415-425 (1993) . 5. Gao,J.-L. et al . J . Exp. Med.177, 1421 -1427 (1993) . 6. Bacon, K.B., Premack,B .A. , Gardner, P. & Schall,T.J. Science 269, 1727-1729 (1995) . 7. Raport,C.J. etal. J. Leukoc. Biol. 59,18-23 (1996) . 8. Wells, T.N.C. et al . J. Leukoc. Biol. 59, 53-60 (1996) . 9. Feng,Y., Broder, CC , Kennedy, P.E. & Berger, E.A. Science 272, 872-877 (1996) . 10. Chen,B.K., Saksela,K., Andino,R. & Baltimore, D. J. Virol. 68, 654-660 (1994) . 11. Connor, R. I., Chen,B.K., Choe,S. , & Landau,N.R. Virology 206, 935-944 (1995) . 12. Lusso,P. etal. J. Virol. 69, 3712-3720 (1995) . 13. Charo,l.F. et al . Proc. Natl. Acad. Sci. USA 91, 2752-2756 (1994) . 14. Ben-Baruch,A. et al . J. Biol. Chem. 270, 22123-22128 (1995) . 15. Combadiere,C etal. J. Biol. Chem. 270, 29671-29675 (1995) . 16. Lip,J.P. , D'Andrea,A.D. , Lodish,H.F. & Baltimore, D. Nature 343, 762-764 (1990) . 17. Litwin,V. et al . J. Virol, (submitted for publication) . 18. Moore, J. P., Jameson, B.A. , Weiss, R.A. & Sattentau, Q.J. in Viral Fusion Mechanisms (ed Bentz,J.) 233-289 (CRC Press Ine, Boca Raton, USA, 1993) . 19. Maddon,P.J. et al . Cell 47, 333-348 (1986) . 20. Ashorn,P.A., Berger, E.A. & Moss,B. J.Virol. 64, 2149-2156 (1990) . 21. Clapham, P.R. , Blanc,D. & Weiss, R.A. Virology 181, 703-715 (1991) . 22. Samson,M. , Labbe,0., Mollereau,C, Vassart,G. & Parmentier,M. Biochemistry 11, 3362-3367 (1996) . 23. Dragic,T., Charneau,P., Clavel,F. & Alizon,M. J.Virol. 66, 4794-4802 (1992) 24. Loetscher,M. et al . J.Biol.Chem. 269, 232-237 (1994) . 25. Moore,J. P. & Ho,D.D. AIDS 9 (suppl A) , S117-S136 (1995) . 26. Trkola,A. & Moore, J. P. (unpublished data) . 27. Chaudhuri,A. , et al. 1994. J.Biol.Chem. 269, 7835-7838 (1994) . 28. Neote,K., Mak,J.Y., Kolakowski Jr. ,L.F. & Schall,T.J. Blood 84, 44-52 (1994) . 29. Dragic,T., Picard,L. &Alizon,M. J.Virol. 69, 1013-1018 (1995) . 30. Puri,A., Morris, S.J., Jones,P., Ryan,M. & Blumenthal,R. Virology 219, 262-267 (1996) .31 THIRD SERIES OF EXPERIMENTS The chemokine SDF-1 (stromal cell-derived factor 1) is the natural ligand for Fusin/CXCR4 and blocks infection by laboratory-adapted strains of HIV-l (Ref. 1 and 2) . SDF-1 exists as at least two forms, SDF-lα and SDF-lβ based on variable splicing of the SDF-1 gene (Ref. 1 and 3) In the RET assay, this chemokine specifically inhibits membrane fusion mediated by gpl20/gp41 form the laboratory-adapted strain HIV^ but not by gpl20/gp41 from the macrophage- tropic isolate HIV-1 JR . FL as shown in Figure 5. References of the Third Series of Experiments 1. Bleul, C . , et al . (1996) Nature 382:829-833 2. Oberlin, E., et al . (1996) Na ture 382:833-835 3. Shirozu, M. , et al. (1995) Genomics 28:495-500 SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANTS: Alla ay, Graham P Litwin, Virginia M Maddon, Paul J Olson, William C (ii) TITLE OF INVENTION: A Method For Preventing HIV-l Infection of CD4+ Cells (iii) NUMBER OF SEQUENCES: 27 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Cooper & Dunham LLP (B) STREET: 1185 Avenue of the Americas (C) CITY: New York (D) STATE: New York (E) COUNTRY: USA (F) ZIP: 10036 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER : ( B ) FILING DATE : (C) CLASSIFICATION: (viii) ATTORNE /AGENT INFORMATION: (A) NAME: White, John P (B) REGISTRATION NUMBER: 28678 (C) REFERENCE/DOCKET NUMBER: 50875-C-PCT/JPW/AKC (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 212-278-0400 (B) TELEFAX: 212-391-0525 (2) INFORMATION FOR SEQ ID NO: 1 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1 : CAAGGCTACT TCCCTGATTG GCAGAACTAC ACACCAGG 38 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (11) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2 : AGCAAGCCGA GTCCTGCGTC GAGAG 25 (2) INFORMATION FOR SEQ ID NO: 3. (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: Single (D) TOPOLOGY, linear (ii) MOLECULE TYPE- oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3 : GGGACTTTCC GCTGGGGACT TTC 23 (2) INFORMATION FOR SEQ ID NO:4 : (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: Single (D) TOPOLOGY linear (ii) MOLECULE TYPE oligonucleotide (Xl) SEQUENCE DESCRIPTION: SEQ ID NO:4: CCTGTTCGGG CGCCACTGCT AGAGATTTTC CAC 33 (2) INFORMATION FOR SEQ ID NO: 5 : (l) SEQUENCE CHARACTERISTICS: (A) LENGTH- 60 amino acids (B) TYPE: ammo acid (C) STRANDEDNESS: n/a (D) TOPOLOGY, n/a (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5 : Pro Cys Cys Phe Ala Tyr lie Ala Arg Pro Leu Pro Arg Ala His lie Lys 1 5 10 15 Glu Tyr Phe Tyr Thr Ser Gly Lys Cys Ser Asn Pro Ala Val Val Phe Val 20 25 30 Thr Arg Lys Asn Arg Gin Val Cys Ala Asn Pro Glu Lys Lys Trp Val Arg 35 40 45 50 Glu Tyr lie Asn Ser Leu Glu Met Ser 55 60 (2) INFORMATION FOR SEQ ID NO:6 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: AAGCTTGGAG AACCAGCGGT TACCATGGAG GGGATC 36 (2) INFORMATION FOR SEQ ID NO:7 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7 GTCTGAGTCT GAGTCAAGCT TGGAGAACCA 30 (2) INFORMATION FOR SEQ ID NO:8 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 41 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8 CTCGAGCATC TGTGTTAGCT GGAGTGAAAA CTTGAAGACT C 41 (2) INFORMATION FOR SEQ ID NO:9 : (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: GTCTGAGTCT GAGTCCTCGA GCATCTGTGT 30 (2) INFORMATION FOR SEQ ID NO:10: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS- single (D) TOPOLOGY: linear (11) MOLECULE TYPE: oligonucleotide (x ) SEQUENCE DESCRIPTION: SEQ ID NO: 10: AAGCTTCAGA GAGAAGCCGG GATGGAAACT CC 32 (2) INFORMATION FOR SEQ ID NO:11: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: GTCTGAGTCT GAGTCAAGCT TCAGAGAGAA 30 (2) INFORMATION FOR SEQ ID NO:12: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12 : CTCGAGCTGA GTCAGAACCC AGCAGAGAGT TC 32 (2) INFORMATION FOR SEQ ID NO:13: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: Single (D) TOPOLOGY: linear (ii) MOLECULE TYPE, oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: GTCTGAGTCT GAGTCCTCGA GCTGAGTCAG 30 (2) INFORMATION FOR SEQ ID NO: 14: (l) SEQUENCE CHARACTERISTICS- (A) LENGTH: 32 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: Single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: AAGCTTCAGT ACATCCACAA CATGCTGTCC AC 32 (2) INFORMATION FOR SEQ ID NO:15: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: GTCTGAGTCT GAGTCAAGCT TCAGTACATC 30 (2) INFORMATION FOR SEQ ID NO:16: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i) MOLECULE TYPE oligonucleotide (x ) SEQUENCE DESCRIPTION: SEQ ID NO:16. CTCGAGCCTC GTTTTATAAA CCAGCCGAGA C 31 (2) INFORMATION FOR SEQ ID NO:17: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17- GTCTGAGTCT GAGTCCTCGA GCCTCGTTTT 30 (2) INFORMATION FOR SEQ ID NO:18. (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: Single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: AAGCTTCAGG GAGAAGTGAA ATGACAACC 29 (2) INFORMATION FOR SEQ ID NO: 19: - (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (11) MOLECULE TYPE: oligonucleotide (Xl) SEQUENCE DESCRIPTION: SEQ ID NO:19: GTCTGAGTCT GAGTCAAGCT TCAGGGAGAA 30 (2) INFORMATION FOR SEQ ID NO:20: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH 33 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20 CTCGAGCAGA CCTAAAACAC AATAGAGAGT TCC 33 (2) INFORMATION FOR SEQ ID NO:21- (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: Single (D) TOPOLOGY, linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: GTCTGAGTCT GAGTCCTCGA GCAGACCTAA 30 (2) INFORMATION FOR SEQ ID NO:22: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: Single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (Xl) SEQUENCE DESCRIPTION: SEQ ID NO-.22: AAGCTTCTGT AGAGTTAAAA AATGAACCCC ACGG 34 (2) INFORMATION FOR SEQ ID NO:23: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ' (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: GTCTGAGTCT GAGTCAAGCT TCTGTAGAGT 30 (2) INFORMATION FOR SEQ ID NO:24: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: CTCGAGCCAT TTCATTTTTC TACAGGACAG CATC 34 (2) INFORMATION FOR SEQ ID NO:25: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: GTCTGAGTCT GAGTCCTCGA GCCATTTCAT 30 (2) INFORMATION FOR SEQ ID NO:26: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: GTCTGAGTCT GAGTCAAGCT TAACAAGATG GATTATCAA 39 (2) INFORMATION FOR SEQ ID NO:27: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i) MOLECULE TYPE: oligonucleotides (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: GTCTGAGTCT GAGTCCTCGA GTCCGTGTCA CAAGCCCAC 39

Claims: What is claimed is: 1. A method for inhibiting fusion of HIV-l to CD4 T cells which comprises contacting CD4 + cells with a non- chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-l to the CD4 * cells is inhibited. 2. A method for inhibiting HIV-l infection of CD4 * cells which comprises contacting CD4 + cells with a non- chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-l to the CD4" cells is inhibited, thereby inhibiting HIV-l infection. 3. The method of claim 1 or 2, wherein the non-chemokine agent is an oligopeptide. 4. The method of claim 1 or 2, wherein the non-chemokine agent is a polypeptide. 5. The method of claim 1 or 2, wherein the non-chemokine agent is an antibody or a portion of an antibody. 6. The method of claim 1 or 2, wherein the non-chemokine agent is a nonpeptidyl agent . 7. A non-chemokine agent capable of binding to a chemokine receptor and inhibiting fusion of HIV-l to CD4 + cells. 8. The non-chemokine agent of claim 7, wherein the non- chemokine agent is a oligopeptide. 9. The non-chemokine agent of claim 7, wherein the non- chemokine agent is a nonpeptidyl agent. 10. The non-chemokine agent of claim 7, wherein the non- chemokine agent is a polypeptide. 11. The non-chemokine agent of claim 10, wherein the polypeptide is an antibody or a portion of an antibody. 12. The non-chemokine agent of claim 10, wherein the polypeptide comprises amino acid sequence as set forth in SEQ ID NO:5. 13. The non-chemokine agent of claim 10, wherein the polypeptide comprises the MIP-lβ sequence with the deletion of the first seven N-terminal amino acids of said sequence. 14. The non-chemokine agent of claim 10, wherein the polypeptide comprises the MIP-lS sequence with the deletion of the first eight N-terminal amino acids of said sequence. 15. The non-chemokine agent of claim 10, wherein the polypeptide comprises the MIP-lβ sequence with the deletion of the first nine N-terminal amino acids of said sequence. 16. The non-chemokine agent of claim 10, wherein the polypeptide comprises the MIP-lS sequence with the deletion of the first ten N-terminal amino acids of said sequence. 17. The non-chemokine agent of claim 10, wherein the polypeptide comprises the MIP-lβ sequence with the N- terminal sequence modified by addition of an amino acid or oligopeptide. 18. The non-chemokine agent of claim 10, wherein the polypeptide comprises the MIP-lβ sequence with the N- terminal sequence modified by removing the N-terminal alanine and replacing it by serine or threonine and an additional amino acid or oligopeptide or nonpeptidyl moiety. 19. The non-chemokine agent of claim 17 or 18, wherein the additional amino acid is methionine. 20. An agent capable of binding to CXCR4 and inhibiting HIV-l infection. 21. The agent of claim 20, wherein the agent is an oligopeptide. 22. The agent of claim 20, wherein the agent is a polypeptide. 23. The non-chemokine agent of claim 22, wherein the polypeptide comprises the SDF-1 sequence with the deletion of the first six N-terminal amino acids of said sequence. 24. The non-chemokine agent of claim 22, wherein the polypeptide comprises the SDF-1 sequence with the deletion of the first seven N-terminal amino acids of said sequence. 25. The non-chemokine agent of claim 22, wherein the polypeptide comprises the SDF-1 sequence with the deletion of the first eight N-terminal amino acids of said sequence. 26. The non-chemokine agent of claim 22, wherein the polypeptide comprises the SDF-1 sequence with the deletion of the first nine N-terminal amino acids of said sequence. 27. The non-chemokine agent of claim 22, wherein the N- terminal glycine of SDF-1 is replaced by serine and derivatized with biotin. 28. The non-chemokine agent of claim 22, wherein the N- terminal glycine of SDF-1 is replaced by serine and derivatized with methionine. 29. The non-chemokine agent of claim 22, wherein the N- terminus of SDF-1 is modified by the addition of a methionine before the terminal glycine. 30. The agent of claim 22, wherein the agent is an antibody or a portion of an antibody. 31. The agent of claim 20, wherein the agent is a non¬ peptidyl agent. 32. A pharmaceutical composition comprising an amount of the non-chemokine agent of claim 7 effective to inhibit fusion of HIV-l to CD4 + cells and a pharmaceutically acceptable carrier. 33. A pharmaceutical composition comprising an amount of the non-chemokine agent of claim 20 effective to inhibit fusion of HIV-l to CD4 + cells and a pharmaceutically acceptable carrier. 34. A composition of matter capable of binding to a chemokine receptor and inhibiting fusion of HIV-l to CD4* cells comprising a non-chemokine agent linked to a ligand capable of binding to a cell surface receptor of the CD4 + cells other than the chemokine receptor such that the binding of the non-chemokine agent to the chemokine receptor does not inhibit the binding of the ligand to the other receptor. 35. The composition of matter of claim 34, wherein the cell surface receptor is CD4. 36. The composition of matter of claim 34, wherein the ligand comprises an antibody or a portion of an antibody. 37. A pharmaceutical composition comprising an amount of the composition of matter of claim 34 effective to inhibit fusion of HIV-l to CD4 + cells and a pharmaceutically acceptable carrier. 38. A composition of matter capable of binding to the chemokine receptor and inhibiting fusion of HIV-l to CD4 + cells comprising a non-chemokine agent linked to a compound capable of increasing the in vivo half-life of the non-chemokine agent. 39. The composition of matter of claim 38, wherein the compound is polyethylene glycol. 40. A pharmaceutical composition comprising an amount of the composition of claim 38 effective to inhibit fusion of HIV-l to CD4 + cells and a pharmaceutically acceptable carrier. 41. A method for reducing the likelihood of HIV-l infection in a subject comprising administering the pharmaceutical composition of claim 32, 33, 37 or 40 to the subject. 42. A method for treating HIV-l infection in a subject comprising administering the pharmaceutical composition of claim 32, 33, 39 or 40 to the subject. 43. A method for determining whether a non-chemokine agent is capable of inhibiting the fusion of HIV-l to a CD4 * cell which comprises: (a) contacting (i) a CD4 + cell, which is labeled with a first dye, with (ii) a cell expressing the HIV- 1 envelope glycoprotein on its surface, which is labeled with a second dye, in the presence of an excess of the agent under conditions permitting the fusion of the CD4' cell to the cell expressing the HIV-l envelope glycoprotein on its surface in the absence of the agent, the first and second dyes being selected so as to allow resonance energy transfer between the dyes; (b) exposing the product of step (a) to conditions which would result in resonance energy transfer if fusion has occurred; and (c) determining whether there is a reduction of resonance energy transfer, when compared with the resonance energy transfer in the absence of the agent, a decrease in transfer indicating that the agent is capable of inhibiting fusion of HIV-l to CD4 * cells. 44. The method of claim 43, wherein the agent is an oligopeptide . 45. The method of claim 43, wherein the agent is a polypeptide. 46. The method of claim 43, wherein the agent is an antibody or a portion of an antibody. 47. The method of claim 43, wherein the agent is a nonpeptidyl agent. 48. The method of claim 43, wherein the CD4 + cell is a PMl cell. 49. The method of claim 43, wherein the cell expressing the HIV-l envelope glycoprotein is a HeLa cell expressing HIV-1~. ?L gpl20/gp41. 50. The method of claim 43, wherein the cell expressing the HIV-l envelope glycoprotein is a HeLa cell expressing HIV-1^- gpl20/gp41.

Inventors: ALLAWAY GRAHAM P, LITWIN VIRGINIA M, MADDON PAUL J, OLSON WILLIAM C, ALLAWAY, GRAHAM, P., LITWIN, VIRGINIA, M., MADDON, PAUL, J., OLSON, WILLIAM, C.
Applicants: PROGENICS PHARM INC, PROGENICS PHARMACEUTICALS, INC.
Application year: 1997
Main classification: C12N5
IPC codes: A61K31, A61K38, A61K39, A61K45, A61K47, A61P31, C07K7, C07K14, C07K16, C12N5, C12N15